Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189466 | 0.96 | NPC1 (0.47) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL13418866 | 0.91 | EPHX2 (0.48) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL3188648 | 0.91 | EPHX2 (0.53) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL13418891 | 0.90 | EPHX2 (0.45) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL3191240 | 0.89 | NPC1 (0.45) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL1552854 | 0.88 | NPC1 (0.44) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL3203105 | 0.87 | NPC1 (0.45) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL1553604 | 0.85 | NPC1 (0.41) | NPC1RAB9AEPHX2HTTSMN1; SMN2 | |
| SCHEMBL1553553 | 0.85 | ABL1 (0.42) | ABL1PIM1MAPK1AURKB | |
| SCHEMBL1553751 | 0.85 | NPC1 (0.43) | NPC1ABL1PIM1MAPK1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-7674801-B2 | Alkyl urea substituted pyridines | ASTRAZENECA AB (SE) | 2010-03-09 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080132546-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132546-A1 | CHEMICAL COMPOUNDS | MRPL21, NISCH, ABCB11 | NPC1 207/4885RAB9A 1867/4885EPHX2 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.